Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$7.42 USD
+0.12 (1.64%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Trevi Therapeutics, Inc. has a market cap of $856.24M, which represents its share price of $7.30 multiplied by its outstanding shares number of 117.29M. As a small-cap company, TRVI's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TRVI 7.42 +0.12(1.64%)
Will TRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVI
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Other News for TRVI
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
TRVI Receives Updated Analyst Rating from Raymond James | TRVI Stock News
Trevi Therapeutics price target lowered by $2 at Raymond James, here's why
Needham Lowers Price Target for Trevi Therapeutics (TRVI) While Maintaining Buy Rating | TRVI ...